NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|1834094501|gb|KAF4265553|]
View 

hypothetical protein CNMCM8714_006473 [Aspergillus fumigatus]

Protein Classification

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
leuko_A4_hydro super family cl37108
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
10-611 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


The actual alignment was detected with superfamily member TIGR02411:

Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 797.06  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  10 DPNTLSNYNNWVSTHITANFDILFDQRKLAGNVIHRFRSTTDGEsNHIILDTNHLDIGSVKVNGQPSEWEYLPRLEPYGT 89
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNL-NKLVLDTSYLDIQKVTINGLPADFAIGERKEPLGS 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  90 PLKIKLDQGVKLNETIEVDISVQTTEKCTALQWLTPAQTSNKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSPL 169
Cdd:TIGR02411  80 PLTISLPIATSKNDEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESPL 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 170 PVIASGLPVRGSSEAPksdGKTLykFHQKVPIPSYLFALASGDISEAPIGPRSVVATSPDKLGECQWELEADTEKFINAI 249
Cdd:TIGR02411 160 PVLMSGIRDGETSNDP---GKYL--FKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFENDTEKFIKTA 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 250 EKIVYPYVWGEYNVLILPPSFPYGGMENPIFTFATPSIISKDRENIDVIAHELAHSWSGNLVTNASWEHFWLNEGWTTYL 329
Cdd:TIGR02411 235 EDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYL 314
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 330 ERRIVAAVHGEPYRHFSAIIGWKALTDSVEHFGPEHDFTKLITNLKGMDPDDAFSSIPYEKGFNFLFHLENLVG-KSKFD 408
Cdd:TIGR02411 315 ERRIIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGgPAEFD 394
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 409 RFIPHYFNKYKGKSLDSYEFKSTILDFFKDDSDASTaLNELDWDSWFYAPGLPP-KPDFDTSLVDVVYDLAKKWLSLPKS 487
Cdd:TIGR02411 395 PFLRHYFKKFAYKSLDTYQFKDALYEYFKDKKKVDK-LDAVDWETWLYSPGMPPvKPNFDTTLADECYALADRWVDAAKA 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 488 SF--KPQPEDIRGLTANQVVVFLEQIL--VSERQLTPELSKLMGEIYGLAASQNIEVANLYFQVGLQAGDASVVEPTADL 563
Cdd:TIGR02411 474 DDlsSFNAKDIKDFSSHQLVLFLETLTerGGDWALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADW 553
                         570       580       590       600
                  ....*....|....*....|....*....|....*....|....*....
gi 1834094501 564 LGKIGRMKFVRPLYRKLAKF-DRKRALDTFEKHKGFYHPICRAMVEKDL 611
Cdd:TIGR02411 554 LGTVGRMKFVRPGYRLLNAFvDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
 
Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
10-611 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 797.06  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  10 DPNTLSNYNNWVSTHITANFDILFDQRKLAGNVIHRFRSTTDGEsNHIILDTNHLDIGSVKVNGQPSEWEYLPRLEPYGT 89
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNL-NKLVLDTSYLDIQKVTINGLPADFAIGERKEPLGS 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  90 PLKIKLDQGVKLNETIEVDISVQTTEKCTALQWLTPAQTSNKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSPL 169
Cdd:TIGR02411  80 PLTISLPIATSKNDEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESPL 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 170 PVIASGLPVRGSSEAPksdGKTLykFHQKVPIPSYLFALASGDISEAPIGPRSVVATSPDKLGECQWELEADTEKFINAI 249
Cdd:TIGR02411 160 PVLMSGIRDGETSNDP---GKYL--FKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFENDTEKFIKTA 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 250 EKIVYPYVWGEYNVLILPPSFPYGGMENPIFTFATPSIISKDRENIDVIAHELAHSWSGNLVTNASWEHFWLNEGWTTYL 329
Cdd:TIGR02411 235 EDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYL 314
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 330 ERRIVAAVHGEPYRHFSAIIGWKALTDSVEHFGPEHDFTKLITNLKGMDPDDAFSSIPYEKGFNFLFHLENLVG-KSKFD 408
Cdd:TIGR02411 315 ERRIIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGgPAEFD 394
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 409 RFIPHYFNKYKGKSLDSYEFKSTILDFFKDDSDASTaLNELDWDSWFYAPGLPP-KPDFDTSLVDVVYDLAKKWLSLPKS 487
Cdd:TIGR02411 395 PFLRHYFKKFAYKSLDTYQFKDALYEYFKDKKKVDK-LDAVDWETWLYSPGMPPvKPNFDTTLADECYALADRWVDAAKA 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 488 SF--KPQPEDIRGLTANQVVVFLEQIL--VSERQLTPELSKLMGEIYGLAASQNIEVANLYFQVGLQAGDASVVEPTADL 563
Cdd:TIGR02411 474 DDlsSFNAKDIKDFSSHQLVLFLETLTerGGDWALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADW 553
                         570       580       590       600
                  ....*....|....*....|....*....|....*....|....*....
gi 1834094501 564 LGKIGRMKFVRPLYRKLAKF-DRKRALDTFEKHKGFYHPICRAMVEKDL 611
Cdd:TIGR02411 554 LGTVGRMKFVRPGYRLLNAFvDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
10-456 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 709.23  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  10 DPNTLSNYNNWVSTHITANFDILFDQRKLAGNVIHRFRSTTDGeSNHIILDTNHLDIGSVKVNG-QPSEWEYLPRLEPYG 88
Cdd:cd09599     1 DPSSFSNYDEVRTTHLDLDLTVDFDKKTISGSATLTLEVLQDG-ADELVLDTRDLDISSVTVNGgKELKFELGPRDPVLG 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  89 TPLKIKLDQGVKLNETIEVDISVQTTEKCTALQWLTPAQTSNKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSP 168
Cdd:cd09599    80 SALTITLPSPLAKGDTFKVKIEYSTTPQATALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQDTPSVKSTYSATVTVP 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 169 --LPVIASGLPVrgssEAPKSDGKTLYKFHQKVPIPSYLFALASGDISEAPIGPRSVVATSPDKLgECQWELEADTEKFI 246
Cdd:cd09599   160 kgLTALMSALRT----GEKEEAGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVV-DAAAEEFADTEKFL 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 247 NAIEKIVYPYVWGEYNVLILPPSFPYGGMENPIFTFATPSIISKDRENIDVIAHELAHSWSGNLVTNASWEHFWLNEGWT 326
Cdd:cd09599   235 KAAEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFT 314
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 327 TYLERRIVAAVHGEPYRHFSAIIGWKALTDSVEHFGPEHDFTKLITNLKGMDPDDAFSSIPYEKGFNFLFHLENLVGKSK 406
Cdd:cd09599   315 VYLERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLLVPDLKGVDPDDAFSSVPYEKGFQFLYYLEQLGGREV 394
                         410       420       430       440       450
                  ....*....|....*....|....*....|....*....|....*....|
gi 1834094501 407 FDRFIPHYFNKYKGKSLDSYEFKSTILDFFKDdsDASTALNELDWDSWFY 456
Cdd:cd09599   395 FDPFLRAYFKKFAFQSIDTEDFKDFLLEYFAE--DKPEILDKIDWDAWLY 442
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
23-589 2.87e-91

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 294.24  E-value: 2.87e-91
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  23 THITANFDILFDQRKLAGNVIHRFRSTTDGeSNHIILDTNHLDIGSVKVNGQPSEWEYlprlepYGTPLKIKLDQGVKLN 102
Cdd:COG0308    18 THYDLDLDLDPATTRLSGTATITFTATEAP-LDSLVLDLKGLEVTSVTVDGKPLDFTR------DGERLTITLPKPLAPG 90
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 103 ETIEVDISVQTT--EKCTALQWLTPAQtsnKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSPLP--VIASGLPV 178
Cdd:COG0308    91 ETFTLEIEYSGKpsNGGEGLYRSGDPP---DGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTVPAGwvAVSNGNLV 167
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 179 rgsSEAPKSDGKTLYKFHQKVPIPSYLFALASGDI----SEAPIGPRSVVATSPDKLGECQWELEaDTEKFINAIEKIV- 253
Cdd:COG0308   168 ---SETELGDGRTTWHWADTQPIPTYLFALAAGDYavveDTFASGVPLRVYVRPGLADKAKEAFE-STKRMLDFFEELFg 243
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 254 YPYVWGEYNVLILPpSFPYGGMENP---IFT---FATPSIISKDRENID-VIAHELAHSWSGNLVTNASWEHFWLNEGWT 326
Cdd:COG0308   244 VPYPFDKYDQVAVP-DFNFGAMENQglvTFGekvLADETATDADYERREsVIAHELAHQWFGNLVTCADWDDLWLNEGFA 322
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 327 TYLERRIVAAVHGEPYRHFSAIIGWKALTDSvehfGPEHDFTKLITNLKGMDPDDAFSSIPYEKGFNFLFHLENLVGKSK 406
Cdd:COG0308   323 TYMEQLFSEDLYGKDAADRIFVGALRSYAFA----EDAGPNAHPIRPDDYPEIENFFDGIVYEKGALVLHMLRTLLGDEA 398
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 407 FDRFIPHYFNKYKGKSLDSYEFkstiLDFFKDDSDAStaLNELdWDSWFYAPGLPpkpdfdTSLVDVVYDLAKKW-LSLP 485
Cdd:COG0308   399 FRAGLRLYFARHAGGNATTEDF----LAALEEASGRD--LSAF-FDQWLYQAGLP------TLEVEYEYDADGKVtLTLR 465
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 486 KSSFKPQPEDI-------RG--------LTANQVVVFLEQILVSERQLTPELSKLM----------GEIYGLAASQNIEV 540
Cdd:COG0308   466 QTPPRPHPFHIplevgllGGkltartvlLDGEQTELVAKPDPVLLLRLDDELAFLLahdsdpfnrwEALQALWRDGEADY 545
                         570       580       590       600       610
                  ....*....|....*....|....*....|....*....|....*....|....*..
gi 1834094501 541 ANLYFQvgLQAGDASVVEPTADLLGK--------IGRMKFVRPLYRKLAKFDRKRAL 589
Cdd:COG0308   546 LDALRA--LADTDPAVRAEALALLGSdqlalaraALALAAELALLRALDDLLALAAL 600
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
236-454 1.52e-53

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 182.10  E-value: 1.52e-53
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 236 WELEADTEKFINAIEKIVYPYVWGEYNVLILPpSFPYGGMENPIFTFATP---------SIISKDRENIDVIAHELAHSW 306
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALP-DFSAGAMENWGLITYREtlllydpgnSSTSDKQRVASVIAHELAHQW 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 307 SGNLVTNASWEHFWLNEGWTTYLERRIVAAVHGE--PYRHFSAIIGWKAL-TDSVehfGPEHDFTKLITnlKGMDPDDAF 383
Cdd:pfam01433  80 FGNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEwnIWEQFLLDEVQNAMaRDAL---DSSHPITQNVN--DPSEIDDIF 154
                         170       180       190       200       210       220       230
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 1834094501 384 SSIPYEKGFNFLFHLENLVGKSKFDRFIPHYFNKYKGKSLDSYEFKSTIldffkddsdaSTALNELD----WDSW 454
Cdd:pfam01433 155 DAIPYEKGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDAL----------SEASGPLDvdsfMDTW 219
 
Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
10-611 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 797.06  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  10 DPNTLSNYNNWVSTHITANFDILFDQRKLAGNVIHRFRSTTDGEsNHIILDTNHLDIGSVKVNGQPSEWEYLPRLEPYGT 89
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNL-NKLVLDTSYLDIQKVTINGLPADFAIGERKEPLGS 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  90 PLKIKLDQGVKLNETIEVDISVQTTEKCTALQWLTPAQTSNKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSPL 169
Cdd:TIGR02411  80 PLTISLPIATSKNDEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESPL 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 170 PVIASGLPVRGSSEAPksdGKTLykFHQKVPIPSYLFALASGDISEAPIGPRSVVATSPDKLGECQWELEADTEKFINAI 249
Cdd:TIGR02411 160 PVLMSGIRDGETSNDP---GKYL--FKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFENDTEKFIKTA 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 250 EKIVYPYVWGEYNVLILPPSFPYGGMENPIFTFATPSIISKDRENIDVIAHELAHSWSGNLVTNASWEHFWLNEGWTTYL 329
Cdd:TIGR02411 235 EDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYL 314
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 330 ERRIVAAVHGEPYRHFSAIIGWKALTDSVEHFGPEHDFTKLITNLKGMDPDDAFSSIPYEKGFNFLFHLENLVG-KSKFD 408
Cdd:TIGR02411 315 ERRIIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGgPAEFD 394
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 409 RFIPHYFNKYKGKSLDSYEFKSTILDFFKDDSDASTaLNELDWDSWFYAPGLPP-KPDFDTSLVDVVYDLAKKWLSLPKS 487
Cdd:TIGR02411 395 PFLRHYFKKFAYKSLDTYQFKDALYEYFKDKKKVDK-LDAVDWETWLYSPGMPPvKPNFDTTLADECYALADRWVDAAKA 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 488 SF--KPQPEDIRGLTANQVVVFLEQIL--VSERQLTPELSKLMGEIYGLAASQNIEVANLYFQVGLQAGDASVVEPTADL 563
Cdd:TIGR02411 474 DDlsSFNAKDIKDFSSHQLVLFLETLTerGGDWALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADW 553
                         570       580       590       600
                  ....*....|....*....|....*....|....*....|....*....
gi 1834094501 564 LGKIGRMKFVRPLYRKLAKF-DRKRALDTFEKHKGFYHPICRAMVEKDL 611
Cdd:TIGR02411 554 LGTVGRMKFVRPGYRLLNAFvDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
10-456 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 709.23  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  10 DPNTLSNYNNWVSTHITANFDILFDQRKLAGNVIHRFRSTTDGeSNHIILDTNHLDIGSVKVNG-QPSEWEYLPRLEPYG 88
Cdd:cd09599     1 DPSSFSNYDEVRTTHLDLDLTVDFDKKTISGSATLTLEVLQDG-ADELVLDTRDLDISSVTVNGgKELKFELGPRDPVLG 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  89 TPLKIKLDQGVKLNETIEVDISVQTTEKCTALQWLTPAQTSNKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSP 168
Cdd:cd09599    80 SALTITLPSPLAKGDTFKVKIEYSTTPQATALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQDTPSVKSTYSATVTVP 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 169 --LPVIASGLPVrgssEAPKSDGKTLYKFHQKVPIPSYLFALASGDISEAPIGPRSVVATSPDKLgECQWELEADTEKFI 246
Cdd:cd09599   160 kgLTALMSALRT----GEKEEAGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVV-DAAAEEFADTEKFL 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 247 NAIEKIVYPYVWGEYNVLILPPSFPYGGMENPIFTFATPSIISKDRENIDVIAHELAHSWSGNLVTNASWEHFWLNEGWT 326
Cdd:cd09599   235 KAAEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFT 314
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 327 TYLERRIVAAVHGEPYRHFSAIIGWKALTDSVEHFGPEHDFTKLITNLKGMDPDDAFSSIPYEKGFNFLFHLENLVGKSK 406
Cdd:cd09599   315 VYLERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLLVPDLKGVDPDDAFSSVPYEKGFQFLYYLEQLGGREV 394
                         410       420       430       440       450
                  ....*....|....*....|....*....|....*....|....*....|
gi 1834094501 407 FDRFIPHYFNKYKGKSLDSYEFKSTILDFFKDdsDASTALNELDWDSWFY 456
Cdd:cd09599   395 FDPFLRAYFKKFAFQSIDTEDFKDFLLEYFAE--DKPEILDKIDWDAWLY 442
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
23-423 9.53e-103

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 317.85  E-value: 9.53e-103
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  23 THITANFDILFDQRKLAGNVIHRFRSTTDGESnhIILDTNHLDIGSVKVNGQPSEWEYLPRLEpyGTPLKIKLDQGVklN 102
Cdd:cd09595     1 YHYDLDLDVDFTTKTLNGTETLTVDASQVGRE--LVLDLVGLTIHSVSVNGAAVDFGEREHYD--GEKLTIPGPKPP--G 74
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 103 ETIEVDISVQTTEKCTALQWLTpAQTSNKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSPLP--VIASGLPVRg 180
Cdd:cd09595    75 QTFTVRISFEAKPSKNLLGWLW-EQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPKKdlLASNGALVG- 152
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 181 ssEAPKSDGKTLYKFHQKVPIPSYLFALASGDISEAPIGPRSV------VATSPDKLGECQWELEAdTEKFINAIEK-IV 253
Cdd:cd09595   153 --EETGANGRKTYRFEDTPPIPTYLVAVVVGDLEFKYVTVKSQprvglsVYSEPLQVDQAQYAFDA-TRAALAWFEDyFG 229
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 254 YPYVWGEYNVLILPPsFPYGGMENPIFTFATPSIISKDRENID-------VIAHELAHSWSGNLVTNASWEHFWLNEGWT 326
Cdd:cd09595   230 GPYPLPKYDLLAVPD-FNSGAMENPGLITFRTTYLLRSKVTDTgarsienVIAHELAHQWFGNLVTMRWWNDLWLNEGFA 308
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 327 TYLERRIVAAVHGEPYRHFSAIIGWKALTDSVEHFGPEHDFTKLITnlkGMDPDDAFSSIPYEKGFNFLFHLENLVGKSK 406
Cdd:cd09595   309 VYYENRIMDATFGTSSRHLDQLSGSSDLNTEQLLEDSSPTSTPVRS---PADPDVAYDGVTYAKGALVLRMLEELVGEEA 385
                         410
                  ....*....|....*..
gi 1834094501 407 FDRFIPHYFNKYKGKSL 423
Cdd:cd09595   386 FDKGVQAYFNRHKFKNA 402
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
23-589 2.87e-91

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 294.24  E-value: 2.87e-91
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  23 THITANFDILFDQRKLAGNVIHRFRSTTDGeSNHIILDTNHLDIGSVKVNGQPSEWEYlprlepYGTPLKIKLDQGVKLN 102
Cdd:COG0308    18 THYDLDLDLDPATTRLSGTATITFTATEAP-LDSLVLDLKGLEVTSVTVDGKPLDFTR------DGERLTITLPKPLAPG 90
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 103 ETIEVDISVQTT--EKCTALQWLTPAQtsnKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSPLP--VIASGLPV 178
Cdd:COG0308    91 ETFTLEIEYSGKpsNGGEGLYRSGDPP---DGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTVPAGwvAVSNGNLV 167
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 179 rgsSEAPKSDGKTLYKFHQKVPIPSYLFALASGDI----SEAPIGPRSVVATSPDKLGECQWELEaDTEKFINAIEKIV- 253
Cdd:COG0308   168 ---SETELGDGRTTWHWADTQPIPTYLFALAAGDYavveDTFASGVPLRVYVRPGLADKAKEAFE-STKRMLDFFEELFg 243
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 254 YPYVWGEYNVLILPpSFPYGGMENP---IFT---FATPSIISKDRENID-VIAHELAHSWSGNLVTNASWEHFWLNEGWT 326
Cdd:COG0308   244 VPYPFDKYDQVAVP-DFNFGAMENQglvTFGekvLADETATDADYERREsVIAHELAHQWFGNLVTCADWDDLWLNEGFA 322
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 327 TYLERRIVAAVHGEPYRHFSAIIGWKALTDSvehfGPEHDFTKLITNLKGMDPDDAFSSIPYEKGFNFLFHLENLVGKSK 406
Cdd:COG0308   323 TYMEQLFSEDLYGKDAADRIFVGALRSYAFA----EDAGPNAHPIRPDDYPEIENFFDGIVYEKGALVLHMLRTLLGDEA 398
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 407 FDRFIPHYFNKYKGKSLDSYEFkstiLDFFKDDSDAStaLNELdWDSWFYAPGLPpkpdfdTSLVDVVYDLAKKW-LSLP 485
Cdd:COG0308   399 FRAGLRLYFARHAGGNATTEDF----LAALEEASGRD--LSAF-FDQWLYQAGLP------TLEVEYEYDADGKVtLTLR 465
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 486 KSSFKPQPEDI-------RG--------LTANQVVVFLEQILVSERQLTPELSKLM----------GEIYGLAASQNIEV 540
Cdd:COG0308   466 QTPPRPHPFHIplevgllGGkltartvlLDGEQTELVAKPDPVLLLRLDDELAFLLahdsdpfnrwEALQALWRDGEADY 545
                         570       580       590       600       610
                  ....*....|....*....|....*....|....*....|....*....|....*..
gi 1834094501 541 ANLYFQvgLQAGDASVVEPTADLLGK--------IGRMKFVRPLYRKLAKFDRKRAL 589
Cdd:COG0308   546 LDALRA--LADTDPAVRAEALALLGSdqlalaraALALAAELALLRALDDLLALAAL 600
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
23-456 3.15e-64

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 217.07  E-value: 3.15e-64
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  23 THITANFDILFDQRKLAGNVIHRFRSTTDGESnhIILDTNHLDIGSVKVNGQPseweyLPRLEPYGTPLKIKLDQGVKLN 102
Cdd:cd09603     4 LHYDLDLDYDPATKSLSGTATITFRATQDLDS--LQLDLVGLTVSSVTVDGVP-----AAFFTHDGDKLVITLPRPLAAG 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 103 ETIEVDISVQTTEKcTALQWLTPAQTSNKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSPLP--VIASGLPVrg 180
Cdd:cd09603    77 ETFTVTVRYSGKPR-PAGYPPGDGGGWEEGDDGVWTAGQPEGASTWFPCNDHPDDKATYDITVTVPAGltVVSNGRLV-- 153
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 181 sSEAPKSDGKTLYKFHQKVPIPSYLFALASGD---ISEAPIGPRSVVATSPDKLGECQWELEADTEKFINAIEKIVYPYV 257
Cdd:cd09603   154 -STTTNGGGTTTWHWKMDYPIATYLVTLAVGRyavVEDGSGGGIPLRYYVPPGDAAKAKASFARTPEMLDFFEELFGPYP 232
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 258 WGEYNVLILPPSfpYGGMENPIFTFATPSIISKDRENIDVIAHELAHSWSGNLVTNASWEHFWLNEGWTTYLERRIVAAV 337
Cdd:cd09603   233 FEKYGQVVVPDL--GGGMEHQTATTYGNNFLNGDRGSERLIAHELAHQWFGDSVTCADWADIWLNEGFATYAEWLWSEHK 310
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 338 HGEpYRHFSAIIGWKaltDSVEHFGPEHDftklitnlKGMDPDDAFSSIPYEKGFNFLFHLENLVGKSKFDRFIPHYFNK 417
Cdd:cd09603   311 GGA-DAYRAYLAGQR---QDYLNADPGPG--------RPPDPDDLFDRDVYQKGALVLHMLRNLLGDEAFFAALRAYLAR 378
                         410       420       430       440
                  ....*....|....*....|....*....|....*....|.
gi 1834094501 418 YKGKSLDSYEFKSTIldffkddSDASTAlnELDW--DSWFY 456
Cdd:cd09603   379 YAHGNVTTEDFIAAA-------EEVSGR--DLTWffDQWLY 410
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
236-454 1.52e-53

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 182.10  E-value: 1.52e-53
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 236 WELEADTEKFINAIEKIVYPYVWGEYNVLILPpSFPYGGMENPIFTFATP---------SIISKDRENIDVIAHELAHSW 306
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALP-DFSAGAMENWGLITYREtlllydpgnSSTSDKQRVASVIAHELAHQW 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 307 SGNLVTNASWEHFWLNEGWTTYLERRIVAAVHGE--PYRHFSAIIGWKAL-TDSVehfGPEHDFTKLITnlKGMDPDDAF 383
Cdd:pfam01433  80 FGNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEwnIWEQFLLDEVQNAMaRDAL---DSSHPITQNVN--DPSEIDDIF 154
                         170       180       190       200       210       220       230
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 1834094501 384 SSIPYEKGFNFLFHLENLVGKSKFDRFIPHYFNKYKGKSLDSYEFKSTIldffkddsdaSTALNELD----WDSW 454
Cdd:pfam01433 155 DAIPYEKGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDAL----------SEASGPLDvdsfMDTW 219
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
499-611 6.33e-53

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


Pssm-ID: 462686  Cd Length: 112  Bit Score: 176.53  E-value: 6.33e-53
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 499 LTANQVVVFLEQILvSERQLTPELSKLMGEIYGLAASQNIEVANLYFQVGLQAGDASVVEPTADLLGKIGRMKFVRPLYR 578
Cdd:pfam09127   1 WSSNQKVVFLERLL-EFSPLSPEQLKALDEVYKLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYR 79
                          90       100       110
                  ....*....|....*....|....*....|...
gi 1834094501 579 KLAKFDRKRALDTFEKHKGFYHPICRAMVEKDL 611
Cdd:pfam09127  80 ALNKVDRDLAVETFEKNKDFYHPICRAMVEKDL 112
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
28-422 2.07e-45

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 166.99  E-value: 2.07e-45
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  28 NFDILFDQRKLAGNVIHRFRSTTDgeSNHIILDTNHLDIGSVKVNGQPSEWEYLPRLEPYGTP--LKIKLDQGVKLNETI 105
Cdd:cd09601     6 TLTPDLENFTFSGSVTITLEVLEP--TDTIVLHAKDLTITSASLTLKGGSGIIEVTVVTDEETefLTITLDETLPPGENY 83
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 106 EVDI--SVQTTEKCTALQWLTPAQTSNKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSP--LPVIASGLPVrgs 181
Cdd:cd09601    84 TLSIefTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPkgYTALSNMPPV--- 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 182 SEAPKSDGKTLYKFHQKVPIPSYLFALASGD---ISEAPIGPRSV-VATSPDKLGECQWELEAdTEKFINAIEK---IVY 254
Cdd:cd09601   161 ESTELEDGWKTTTFETTPPMSTYLVAFVVGDfeyIESTTKSGVPVrVYARPGKIEQGDFALEV-APKILDFYEDyfgIPY 239
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 255 PyvwgeynvliLP-------PSFPYGGMENP--IfTFATPSII-------SKDRENI-DVIAHELAHSWSGNLVTNASWE 317
Cdd:cd09601   240 P----------LPkldlvaiPDFAAGAMENWglI-TYRETALLydpktssASDKQRVaEVIAHELAHQWFGNLVTMKWWD 308
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 318 HFWLNEGWTTYLERRIVAAVHGE--PYRHFSAIIGWKAL-TDSvehfgpeHDFTKLITN--LKGMDPDDAFSSIPYEKGF 392
Cdd:cd09601   309 DLWLNEGFATYMEYLAVDKLFPEwnMWDQFVVDELQSALeLDS-------LASSHPIEVpvESPSEISEIFDAISYSKGA 381
                         410       420       430
                  ....*....|....*....|....*....|
gi 1834094501 393 NFLFHLENLVGKSKFDRFIPHYFNKYKGKS 422
Cdd:cd09601   382 SVLRMLENFLGEEVFRKGLRKYLKKHAYGN 411
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
13-454 3.33e-36

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 141.11  E-value: 3.33e-36
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  13 TLSNynnwVSTHITanFDILFDQRKLAGNVIHRFRSTTDGESnhIILDTNHLDIGSVKVNGQPSEWEYLPRLepygtplK 92
Cdd:cd09602    12 LISV----VSYDLD--LDLTEGAETFRGTVTIRFTLREPGAS--LFLDFRGGEVKSVTLNGRPLDPSAFDGE-------R 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  93 IKLDQGVKLNE-TIEVDISVQTTEKCTALQWLT-PAQtsnkKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSP-- 168
Cdd:cd09602    77 ITLPGLLKAGEnTVVVEFTAPYSSDGEGLHRFVdPAD----GETYLYTLFEPDDARRVFPCFDQPDLKATFTLTVTAPad 152
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 169 LPVIASGLPVRgsseAPKSDGKTLYKFHQKVPIPSYLFALASGD---ISEAPIG-PRSVVATSPDKlgecQWELEAD--- 241
Cdd:cd09602   153 WTVISNGPETS----TEEAGGRKRWRFAETPPLSTYLFAFVAGPyhrVEDEHDGiPLGLYCRESLA----EYERDADeif 224
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 242 --TEKFINAIEKI-VYPYVWGEYNvLILPPSFPYGGMENP-IFTF---------ATPSiiskDREN-IDVIAHELAHSWS 307
Cdd:cd09602   225 evTKQGLDFYEDYfGIPYPFGKYD-QVFVPEFNFGAMENPgAVTFresylfreePTRA----QRLRrANTILHEMAHMWF 299
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 308 GNLVTNASWEHFWLNEGWTTYLERRIVAAV--HGEPYRHFSAIIGWKAL-TDSVE--H--FGPehdftklITNLkgmdpD 380
Cdd:cd09602   300 GDLVTMKWWDDLWLNESFADFMAAKALAEAtpFTDAWLTFLLRRKPWAYrADQLPttHpiAQD-------VPDL-----E 367
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 381 DAFS---SIPYEKGFNFLFHLENLVGKSKFDRFIPHYFNKYKgksldsyeFKSTIL-DFFkddsdasTALNE---LDWDS 453
Cdd:cd09602   368 AAGSnfdGITYAKGASVLKQLVALVGEEAFRAGLREYFKKHA--------YGNATLdDLI-------AALDEasgRDLSA 432

                  .
gi 1834094501 454 W 454
Cdd:cd09602   433 W 433
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
21-205 1.14e-27

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 110.13  E-value: 1.14e-27
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  21 VSTHITANFDILFDQRKLAGNVIHRFRSTTdgESNHIILDTNHLDIGSVKVNGQPS------EWEYLPRLEPYgtpLKIK 94
Cdd:pfam17900   1 VPEHYDLDLKIDLKNFTFSGSVTITLQLNN--ATNVIVLHASDLTIRSISLSDEVTsdgvpaDFTEDQKDGEK---LTIV 75
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  95 LDQGVKLNE--TIEVDISVQTTEKCTALQWLTpAQTSNKKHPYMFSQCQAIHARSIFPCQDTPDVKCTLDFNITSPLPVI 172
Cdd:pfam17900  76 LPETLNQTGpyTLEIEYSGELNDSMTGFYRST-YTDNGEKKVLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDYT 154
                         170       180       190
                  ....*....|....*....|....*....|....
gi 1834094501 173 A-SGLPVRgsSEAPKSDGKTLYKFHQKVPIPSYL 205
Cdd:pfam17900 155 AlSNMPVI--ASEPLENGWVITTFEQTPKMSTYL 186
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
64-455 1.71e-26

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 112.75  E-value: 1.71e-26
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  64 LDIGSVKVNGQPSEWEYlprlEPYGTPLKIKLDQGVKLNETIEVDISVQTTekctalqwlTPAQ---TSNKKHPYMFSQC 140
Cdd:cd09604    66 IDIDSVKVNGKGLKLEV----TLTITRLKLALPLPLKPGESVTVEIDFTVK---------LPEQggrFGYDGDEYNLAQW 132
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 141 --------------QAIHARSIFPCQDTpdvkCTLDFNITspLP----VIASGLPVrgsSEAPKSDGKTLYKFHQKvPIP 202
Cdd:cd09604   133 ypklavyddggwntDPYYGRGEFFYSDF----GDYDVTIT--VPknyvVAATGELQ---NPEEVLDGTKTWHFKAE-NVR 202
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 203 SylFALASGD---ISEAPIGPRSVVATSPDKLGEcQWE--LEAdTEKFINAIEKIVYPYVWGEYNVlILPPSFpYGGMEN 277
Cdd:cd09604   203 D--FAWAASPdfvVDAATVDGVTVNVYYLPENAE-AAEraLEY-AKDALEFFSEKFGPYPYPELDV-VQGPFG-GGGMEY 276
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 278 PIFTFATPSIISKDRENIDVIAHELAHSWSGNLVTNASWEHFWLNEGWTTYLERRIVAAVHGEPYrhfsaiiGWKALTDS 357
Cdd:cd09604   277 PGLVFIGSRLYDPKRSLEGVVVHEIAHQWFYGIVGNDERREPWLDEGLATYAESLYLEEKYGKEA-------ADELLGRR 349
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 358 VEHFGPEHDFTKLITNLKGMDPDDAFSSIPYEKGFNFLFHLENLVGKSKFDRFIPHYFNKYKGKSLDSYEFKSTILDFFK 437
Cdd:cd09604   350 YYRAYARGPGGPINLPLDTFPDGSYYSNAVYSKGALFLEELREELGDEAFDKALREYYRRYKFKHPTPEDFFRTAEEVSG 429
                         410
                  ....*....|....*...
gi 1834094501 438 DDsdastaLNELdWDSWF 455
Cdd:cd09604   430 KD------LDWF-FRGWL 440
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
23-443 1.15e-20

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 94.89  E-value: 1.15e-20
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  23 THITANFDiLFDQRKLAGNVIHRFRSTTDGESNHIILDTNHLDIGSVKVNGQPSEWEYLpRLEPYGtpLKIKldqgvKLN 102
Cdd:cd09600    10 DHVDLDFD-LDDDETIVTSRLRVRRNPDSGEGAPLVLDGEDLELLSVKIDGKPLSPSDY-TLDEEG--LTIK-----NVP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 103 ETIEVDISVQTT-EKCTALQWLTpaqtsnkKHPYMF-SQCQAIHARSIFPCQDTPDVKCTLDFNITSP---LPVIAS-GL 176
Cdd:cd09600    81 DRFVLEIEVRINpAANTSLEGLY-------KSGGILcTQCEAEGFRRITYFPDRPDVMSKFTVTIEADkekYPVLLSnGN 153
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 177 PVrgsSEAPKSDGKTLYKFHQKVPIPSYLFALASGDISEA------PIGpRSV---VATSPDKLGECQWELEA------- 240
Cdd:cd09600   154 LI---EEGELPNGRHFAVWEDPFPKPSYLFALVAGDLGSVedtfttKSG-RKVklrIYVEPGNEDKCHHAMESlkkamkw 229
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 241 DTEKFinAIEkivypYVWGEYNVLILPpSFPYGGMENP---IFT---------FATPSiiskDRENI-DVIAHELAHSWS 307
Cdd:cd09600   230 DEERF--GLE-----YDLDLFNIVAVD-DFNMGAMENKglnIFNskyvladpeTATDA----DYERIeSVIAHEYFHNWT 297
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 308 GNLVTNASWEHFWLNEGWTTYLERRIVAAVHGEPYRHFSAIigwKALTDSV--EHFGP-EH----DFTKLITNLkgmdpd 380
Cdd:cd09600   298 GNRVTCRDWFQLSLKEGLTVFRDQEFSADMNSRAVKRIEDV---RRLRSAQfpEDAGPmAHpirpDSYIEINNF------ 368
                         410       420       430       440       450       460
                  ....*....|....*....|....*....|....*....|....*....|....*....|...
gi 1834094501 381 daFSSIPYEKGFNFLFHLENLVGKSKFDRFIPHYFNKYKGKSLdsyefksTILDFFKDDSDAS 443
Cdd:cd09600   369 --YTVTVYEKGAEVIRMLHTLLGEEGFRKGMDLYFERHDGQAV-------TCEDFVAAMEDAS 422
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
255-333 5.51e-18

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 79.45  E-value: 5.51e-18
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 255 PYVWGEYNVLILPP---SFPYGGMENPI-FTFATPSIISKDRENIDVIAHELAHSWSGNLVTN-ASWEHFWLNEGWTTYL 329
Cdd:cd09594    22 YPVSPIYSLLVYPAyveVNAYNAMWIPStNIFYGAGILDTLSGTIDVLAHELTHAFTGQFSNLmYSWSSGWLNEGISDYF 101

                  ....
gi 1834094501 330 ERRI 333
Cdd:cd09594   102 GGLV 105
M1_like_TAF2 cd09839
TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) ...
30-329 1.42e-09

TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) associated factor 2 (TAF2, TBP-associated factor TAFII150, transcription initiation factor TFIID subunit 2, RNA polymerase II TBP-associated factor subunit B), and has homology to the M1 gluzincin family. TAF2 is part of the TFIID multidomain subunit complex essential for transcription of most protein-encoded genes by RNA polymerase II. TAF2 is known to interact with the initiator element (Inr) found at the transcription start site of many genes, thus possibly playing a key role in promoter binding as well as start-site selection. Image analysis has shown TAF2 to form a complex with TAF1 and TBP, inferring its role in promoter recognition. Peptidases in the M1 family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. TAF2, however, lacks these active site residues.


Pssm-ID: 341074 [Multi-domain]  Cd Length: 531  Bit Score: 60.71  E-value: 1.42e-09
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  30 DILFDQRKLAG---NVIHrfrsTTDGESNHIILDTNHLDIGSVKVNGQPSEWEY---LPRLEPYGTP------------- 90
Cdd:cd09839     9 DVDFANRSIIGyteITIV----PTSPDLRTIRLNCRQCKIKSVTVNGVEAEFTYndpLQNLDLSDNTdvnahhelkrkla 84
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501  91 ------------LKIKLDQGVKLNETIEVDISVQTTEKCTA-----------------------LQWLTPAQTSNKKHPY 135
Cdd:cd09839    85 aalaepdegneeLVISLPPSVKIELQDPNSASTQATTSSPDtsedeftpltirieyslknprdgLHFVGPDEGGDKRYPH 164
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 136 MFSQCQAIH--ARSIFPCQDTPDVKCTLDFNITSP----------LPVIASGLPVRGSSEA------------------- 184
Cdd:cd09839   165 VYTTNSPLPgsARCWFPCVDSLWERCTWELEITVPrtlgdagrppLAGSKEDEDDDDLTEEdkelemvvvcsgdlveqvv 244
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 185 -PKSDGKTLYKFHQKVPIPSYLFALAsgdiseapIGPRSVVATSPDKlgecqwELEADTEKFINAIEKIVY--PY--VWG 259
Cdd:cd09839   245 hPEDPSKKTFSFSLSNPTSAQHIGFA--------VGPFEIVPLPEFR------ESEEDDKLGSSAVEVTGFclPGrlEEL 310
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1834094501 260 EYNVLILPP----------SFPYG--------GMENPIFTFATPSIISkDR----ENI--------DVIAHELAHSWSGN 309
Cdd:cd09839   311 RNTCSFLHKamdffeeeygSYPFSsykqvfvdDLPEDVSSFASLSICS-SRllypPDIidqayetrRKLAHALASQWFGI 389
                         410       420
                  ....*....|....*....|
gi 1834094501 310 LVTNASWEHFWLNEGWTTYL 329
Cdd:cd09839   390 NIIPKTWSDTWLVIGIAGYM 409
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH